<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2931">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461551</url>
  </required_header>
  <id_info>
    <org_study_id>OPCAB</org_study_id>
    <nct_id>NCT01461551</nct_id>
  </id_info>
  <brief_title>Anesthesia and Lymphocytes Apoptosis</brief_title>
  <acronym>OPCAB</acronym>
  <official_title>Different Effects of Sevoflurane, Propofol and Combine of Sevoflurane and Propofol Maintained Anesthesia on Peripheral Blood Lymphocytes During Off-pump Coronary Artery Bypass Graft Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most researches revealed that volatile anesthetic sevoflurane has a more marked
      cardioprotective effect against ischemia compared with intravenous agent propofol.However,
      propofol has been suggested to be more benefit for attenuation of surgery-induced
      immunosuppression.Thus, the aim of this study was to investigate under the specific OPCAB
      surgical stress, the influence of 3 established anesthetic techniques: sevoflurane, propofol
      and combine of sevoflurane and propofol maintained anesthesia on the apoptosis of
      circulating lymphocytes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Lymphocyte Count</measure>
    <time_frame>1 day after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood samples were obtained 24 h after the surgery for routine blood examination. This analysis was performed in the hospital laboratory using routine laboratory procedures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Staying Days</measure>
    <time_frame>participants will stay in intensive care unit after surgery, an expected average of 2 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combine of sevoflurane and propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)</description>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combine of sevoflurane and propofol</intervention_name>
    <description>anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)</description>
    <arm_group_label>Combine of sevoflurane and propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male adults

          -  aged 18-80 yr

          -  undergoing elective OPCAB surgery containing left anterior descending artery bypass

        Exclusion Criteria:

          -  a previous unusual response to any of the experimental anesthetics

          -  severe cardiac dysrhythmias or ejection fraction below 30%

          -  hemodynamic instability

          -  previous surgical coronary artery repair

          -  anemia, abnormal leukocytes or coagulopathy

          -  severe hypertension

          -  severe hepatic (albumin&lt;30g,ascites), renal (serum creatinine greater than 2.0 mg/dl)
             or pulmonary (preoperative pulmonary function tests moderate-severe) dysfunctions

          -  concomitant surgical procedures and psychiatric disorders

          -  Insulin-dependent diabetics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bu-Wei Yu, Ph.D., M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Ruijin Hospital, Shanghai Jiao tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.rjh.com.cn/pages/index.shtml</url>
  </link>
  <link>
    <url>http://www.shsmu.edu.cn/</url>
  </link>
  <link>
    <url>http://www.sjtu.edu.cn/</url>
  </link>
  <link>
    <url>http://www.rjh.com.cn/pages/ruijin/ylts/zdxk/7828.shtml</url>
  </link>
  <link>
    <url>http://www.rjh.com.cn/pages/Xinzhangwaike/index.shtml</url>
  </link>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 6, 2015</lastchanged_date>
  <firstreceived_date>October 19, 2011</firstreceived_date>
  <firstreceived_results_date>November 5, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Li-Jie Jia</investigator_full_name>
    <investigator_title>resident</investigator_title>
  </responsible_party>
  <keyword>troponin I</keyword>
  <keyword>creatine kinase mb</keyword>
  <keyword>hospital days</keyword>
  <keyword>lymphocyte apoptosis</keyword>
  <keyword>intensive care unit days</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment took place from October 9, 2011 to January 12, 2012 in Ruijin Hospital. A total of 149 patients scheduled to undergo elective OPCABG surgery were assessed for eligibility, with 105 patients enrolled and allocated randomly.</recruitment_details>
      <pre_assignment_details>A total of 105 patients enrolled and allocated randomly. Five of these patients were excluded after enrollment (four due to changes in surgical schedules, and one due to severe hemodynamic instability during clamping of the coronary artery and requiring cardiopulmonary bypass).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sevoflurane</title>
          <description>Sevoflurane: anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)</description>
        </group>
        <group group_id="P2">
          <title>Propofol</title>
          <description>Propofol: anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)</description>
        </group>
        <group group_id="P3">
          <title>Combine of Sevoflurane and Propofol</title>
          <description>combine of sevoflurane and propofol: anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sevoflurane</title>
          <description>Sevoflurane: anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)</description>
        </group>
        <group group_id="B2">
          <title>Propofol</title>
          <description>Propofol: anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)</description>
        </group>
        <group group_id="B3">
          <title>Combine of Sevoflurane and Propofol</title>
          <description>combine of sevoflurane and propofol: anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61" spread="8"/>
                <measurement group_id="B2" value="62" spread="8"/>
                <measurement group_id="B3" value="65" spread="9"/>
                <measurement group_id="B4" value="63" spread="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="100"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>China</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lymphocyte Count</title>
        <description>Blood samples were obtained 24 h after the surgery for routine blood examination. This analysis was performed in the hospital laboratory using routine laboratory procedures.</description>
        <time_frame>1 day after surgery</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Sevoflurane: anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Propofol: anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)</description>
          </group>
          <group group_id="O3">
            <title>Combine of Sevoflurane and Propofol</title>
            <description>combine of sevoflurane and propofol: anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Lymphocyte Count</title>
            <description>Blood samples were obtained 24 h after the surgery for routine blood examination. This analysis was performed in the hospital laboratory using routine laboratory procedures.</description>
            <units>cells/nanoliter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.55" spread="0.25"/>
                  <measurement group_id="O2" value="0.73" spread="0.27"/>
                  <measurement group_id="O3" value="0.73" spread="0.31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Staying Days</title>
        <time_frame>participants will stay in intensive care unit after surgery, an expected average of 2 days</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sevoflurane</title>
          <description>Sevoflurane: anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)</description>
        </group>
        <group group_id="E2">
          <title>Propofol</title>
          <description>Propofol: anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)</description>
        </group>
        <group group_id="E3">
          <title>Combine of Sevoflurane and Propofol</title>
          <description>combine of sevoflurane and propofol: anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lijie Jia</name_or_title>
      <organization>Ruijin Hospital</organization>
      <phone>13916667704</phone>
      <email>litery0301@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
